The Phase 3 BOREAS trial demonstrated that DUPIXENT reduced moderate-to-severe exacerbations by 30% over 52 weeks and ...

导读近日，慢性阻塞性肺疾病（COPD）全球创议（global initiative for chronic obstructive lung ...

While medical headlines often focus on the biochemical underpinnings of disease, our body's biomechanics are equally crucial.

Childhood body mass index (BMI) is associated with lung health later in life, according to a study published online Oct. 28 ...

Background: Oxidative stress is thought to have a major role in the pathogenesis of airway obstruction. A study was undertaken to determine whether subjects with low levels of antioxidants (serum ...

Good afternoon, and welcome to the MannKind Corporation third quarter 2024 financial results earnings call. As a reminder, ...

A viral Instagram reel claims that Putting Alcohol On Neck can Make Your Cough Disappear. This claim by the Instagram user is ...

慢性阻塞性肺疾病（COPD）是一种持续存在的呼吸系统症状和气流受限的呼吸系统疾病，目前长期氧疗是 COPD 患者稳定期治疗的重要手段，可有效延长严重慢性静息低氧血症患者的生存期，但同时长期氧疗是 COPD ...

Ensifentrine also achieved significant improvements in key measures of lung function in the trial, including the primary endpoint of forced expiratory volume (FEV1) at 12 weeks, as well as in COPD ...

pre-bronchodilator FEV1 at Week 52. Tezepelumab is being developed by AstraZeneca in collaboration with Amgen as a ...

Arcturus Therapeutics (NASDAQ: ARCT)于2024年11月14日召开的2024年第三季度财报电话会议上，分享了公司的财务状况和产品管线进展的最新情况。首席执行官Joe Payne和首席财务官Andy Sassine讨论了公司首个商业化产品KOSTAIVE在日本的上市情况以及财务业绩。 尽管公司报告第三季度净亏损690万美元，相比去年同期有所改善，但公司对未来仍保持乐 ...

There are two types of lung diseases: obstructive lung disease and restrictive lung disease. Both types can cause symptoms like shortness of breath, but a key difference is when you feel like you’re ...